Last reviewed · How we verify
Cisplatin for Injection / Carboplatin Injection
Cisplatin for Injection / Carboplatin Injection is a Platinum-based chemotherapy agent Small molecule drug developed by Shanghai Junshi Bioscience Co., Ltd.. It is currently in Phase 3 development for Various solid tumors (lung cancer, ovarian cancer, testicular cancer, bladder cancer, head and neck cancer), Combination chemotherapy regimens for advanced malignancies.
Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and cause cross-linking, leading to cell death.
Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and cause cross-linking, leading to cell death. Used for Various solid tumors (lung cancer, ovarian cancer, testicular cancer, bladder cancer, head and neck cancer), Combination chemotherapy regimens for advanced malignancies.
At a glance
| Generic name | Cisplatin for Injection / Carboplatin Injection |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Both drugs form covalent adducts with DNA, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription. This results in apoptosis of rapidly dividing cancer cells. Carboplatin is a second-generation platinum compound with a similar mechanism to cisplatin but with a different toxicity profile and improved tolerability.
Approved indications
- Various solid tumors (lung cancer, ovarian cancer, testicular cancer, bladder cancer, head and neck cancer)
- Combination chemotherapy regimens for advanced malignancies
Common side effects
- Nephrotoxicity
- Ototoxicity
- Neuropathy
- Nausea and vomiting
- Myelosuppression
- Anemia
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin for Injection / Carboplatin Injection CI brief — competitive landscape report
- Cisplatin for Injection / Carboplatin Injection updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI
Frequently asked questions about Cisplatin for Injection / Carboplatin Injection
What is Cisplatin for Injection / Carboplatin Injection?
How does Cisplatin for Injection / Carboplatin Injection work?
What is Cisplatin for Injection / Carboplatin Injection used for?
Who makes Cisplatin for Injection / Carboplatin Injection?
What drug class is Cisplatin for Injection / Carboplatin Injection in?
What development phase is Cisplatin for Injection / Carboplatin Injection in?
What are the side effects of Cisplatin for Injection / Carboplatin Injection?
What does Cisplatin for Injection / Carboplatin Injection target?
Related
- Drug class: All Platinum-based chemotherapy agent drugs
- Target: All drugs targeting DNA
- Manufacturer: Shanghai Junshi Bioscience Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various solid tumors (lung cancer, ovarian cancer, testicular cancer, bladder cancer, head and neck cancer)
- Indication: Drugs for Combination chemotherapy regimens for advanced malignancies
- Compare: Cisplatin for Injection / Carboplatin Injection vs similar drugs
- Pricing: Cisplatin for Injection / Carboplatin Injection cost, discount & access